Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Having stated its ambitions to take on global licensing opportunities earlier this year, China’s Harbour BioMed signed its first...








